marketnetra
Sign inStart free

Zydus Lifesciences Limited

NSE: ZYDUSLIFEHealthcareLot size: 900

Zydus Lifesciences Limited Open Interest & PCR Analysis

₹1175.50Updated 28 Oct 2026, 03:30 pm IST
PCR
0.65Bearish signal
Max Pain
₹1160Spot above by ₹16
Total CE OI
1.91MCall writers
Total PE OI
1.23MPut writers
OI Buildup Signal
Neutral
Price movement < 0.3% threshold
Put-Call Ratio Gauge
0 — Bearish1.0 — Neutral2.0+ — Bullish
AI AnalysisGenerated daily after market close · AI-powered

OI Buildup Pattern

The current open‑interest (OI) profile shows a neutral buildup, meaning that neither the price of the underlying nor the total OI has moved appreciably during the reporting period. With the spot price flat at ₹1,175.5 and total OI unchanged at 1,910,700 contracts, there is no discernible dominance of either long‑building or short‑building activity. Consequently, market participants appear to be holding existing positions rather than aggressively adding new longs or shorts, reflecting a balanced stance ahead of the expiry.

Put‑Call Ratio

The put‑call ratio (PCR) stands at 0.646, indicating that call‑buying activity modestly outweighs put‑buying pressure for this expiry. Compared with yesterday’s PCR of 0.753, the ratio has moved lower, suggesting a slight shift toward more call exposure relative to puts.

Futures OI

Futures open interest registers a net zero change, with both the absolute OI and its day‑to‑day variation unchanged at zero contracts. This static futures OI implies that speculative or hedging participants have not altered their net exposure in the underlying futures market.

Data Summary

The key observation for this expiry is a flat total OI of 1,910,700 contracts combined with a neutral buildup, underscoring a market environment of near‑balanced positioning.

Data as of 2026-10-28

Related Analysis

Same Sector

ALKEMAlkem Laboratories LimitedNeutralAPOLLOHOSPApollo Hospitals Enterprise LimitedNeutralAUROPHARMAAurobindo Pharma LimitedNeutralBIOCONBiocon LimitedNeutralCIPLACipla LimitedNeutral

Frequently Asked Questions

What is Zydus Lifesciences Limited PCR (Put-Call Ratio) today?
Zydus Lifesciences Limited's current PCR is 0.65. A PCR above 1.2 is considered bullish (more put writing = floor support); below 0.8 is bearish; 0.8–1.2 is neutral. Zydus Lifesciences Limited's PCR of 0.65 indicates bearish sentiment.
What is Zydus Lifesciences Limited OI buildup type today?
Zydus Lifesciences Limited is currently showing neutral positioning with no significant directional bias. This is determined by comparing today's price change direction with the direction of total OI change — using the standard F&O buildup classification framework.
What is total CE and PE open interest for Zydus Lifesciences Limited?
Zydus Lifesciences Limited has total CE (call) OI of 1910700 contracts and total PE (put) OI of 1234350 contracts for the nearest expiry. The PCR is 0.65.
How is open interest analysis useful for Zydus Lifesciences Limited trading?
OI analysis for Zydus Lifesciences Limited helps identify institutional positioning. High CE OI at a strike = call writers defending that level (resistance). High PE OI = put writers defending that level (support). The buildup type tells you whether smart money is building fresh positions (bullish/bearish) or exiting existing ones.
What is the max pain for Zydus Lifesciences Limited?
Zydus Lifesciences Limited's max pain is ₹1,160 — the strike price where option writers (sellers) collectively suffer the least financial loss at expiry. The current spot price vs max pain deviation guides near-term directional bias into expiry.